RNA Duplexes with Single Stranded Phosphorothioate Nucleotide Regions for Additional Functionality
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application PCT/US2010/000348, filed Feb 4, 2010. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,745,574 | RNA Duplexes with Single Stranded Phosphorothioate Nucleotide Regions for Additional Functionality In force · High confidence | Phio Pharmaceuticals Corp. | In force | High confidence | ||
| US 10,479,992 | RNA Duplexes with Single Stranded Phosphorothioate Nucleotide Regions for Additional Functionality In force · Medium confidence | Phio Pharmaceuticals Corp. | In force | Medium confidence | ||
| US 11,667,915 | RNA Duplexes with Single Stranded Phosphorothioate Nucleotide Regions for Additional Functionality In force · Medium confidence | Phio Pharmaceuticals Corp. | In force | Medium confidence |
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.